As compared to untreated disease, those who remain on a stable regimen despite the presence of drug-resistance mutations have slower rates of CD4+ T cell decline and a lower risk of progressing to AIDS and/or death [1], [2], [3]. This evidence concerns the gene CD4 and AIDS.